Abstract Details

Title Deployment of Portable, Bedside, Low-field Magnetic Resonance Imaging for Evaluation of Stroke Patients

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) S60 - Cerebrovascular Imaging and Biomarkers (1:00 PM-1:12 PM)

Poster/Presentation
Number 001

Objective To determine the safety and feasibility of portable, bedside, low-field MRI in a clinical setting.

Background Conventionally, patients must travel to the location of a high-field MRI device for stroke neuroimaging. Advances in low-field MRI have enabled acquisition of clinically useful images using a portable device at the bedside. The feasibility of using point of care (POC) MRI in a clinical stroke setting is unknown.

Design/Methods POC MRI exams were performed in Yale’s Neuroscience Intensive Care Unit (NICU) from July 2018 to August 2019. Images were acquired at the bedside using a standard 110V, 15A power outlet. The environment included monitors, ventilators and intravenous infusion pumps. Exams were performed by research staff trained to operate the scanner in the absence of an MRI technician. Ferrous metals remained in the room. Scan parameters were controlled using a tablet computer interface, and images were available immediately.

Results POC MRI was obtained in 85 stroke cases (46% female, ages 18-96 years, 46% ischemic stroke, 34% intracerebral hemorrhage, 20% subarachnoid hemorrhage). Scans were obtained within 7 days of symptom onset. NIHSS scores ranged from 1 to 29 (median of 7). Of the 85 patients analyzed, 68 underwent T2-weighted imaging, 72 underwent FLAIR imaging, and 39 underwent diffusion weighted imaging. The majority 74 (87%) of patients completed the exam. Five patients (6%) were unable to fit in the scanner’s 30 cm opening, while 6 patients (7%) experienced claustrophobia resulting in early termination of the exam. Mean exam time was 28.9 ± 8.4 minutes. The 64 mT static magnetic field, gradient and RF pulses of the POC MRI scanner did not interfere with NICU equipment.

Conclusions We report the first use of a portable, low-field MRI system to image stroke patients at the bedside. This early work suggests our approach is safe and viable in a complex clinical care environment.

Authors/Disclosures
Bradley Cahn PRESENTER	Mr. Cahn has nothing to disclose.
Jill T. Shah	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Matthew Yuen (Yale University)	Mr. Yuen has nothing to disclose.
Mercy H. Mazurek (Harvard Medical School)	Miss Mazurek has nothing to disclose.
	No disclosure on file
Sam Payabvash	Sam Payabvash has nothing to disclose.
Rachel Beekman, MD (Yale New Haven Medical Center)	Dr. Beekman has nothing to disclose.
Stacy C. Brown, MD (The Queen's Medical Center, Neuroscience Institute)	Dr. Brown has nothing to disclose.
Guido J. Falcone, MD (Yale School of Medicine)	The institution of Dr. Falcone has received research support from NIH. The institution of Dr. Falcone has received research support from AHA.
Kevin Gobeske, MD (Yale School of Medicine, Neurology)	Dr. Gobeske has nothing to disclose.
Nils Petersen, MD (Yale University)	The institution of Dr. Petersen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Silkroad Medical. Dr. Petersen has received research support from NIH.
Adam S. Jasne, MD (Yale)	Dr. Jasne has nothing to disclose.
Richa Sharma, MD (Massachusetts General Hospital, Brigham, Harvard)	Dr. Sharma has received research support from NIH. Dr. Sharma has received intellectual property interests from a discovery or technology relating to health care.
Joseph L. Schindler, MD (Yale University Department of Neurology)	Dr. Schindler has received personal compensation for serving as an employee of Aeromics. Dr. Schindler has received personal compensation in the range of $50,000-$99,999 for serving as an officer or member of the Board of Directors for Aeromics. Dr. Schindler has received stock or an ownership interest from Aeromics. Dr. Schindler has received publishing royalties from a publication relating to health care.
Lauren H. Sansing, MD	Dr. Sansing has nothing to disclose.
Emily J. Gilmore, MD (Yale University School of Medicine)	Dr. Gilmore has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for carpl.ai. Dr. Gilmore has received personal compensation in the range of $0-$499 for serving as a Consultant for AAN. Dr. Gilmore has received research support from NIH.
Charles Wira	No disclosure on file
Charles Matouk	Charles Matouk has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Silk Road Medical. Charles Matouk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Microvention. Charles Matouk has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Navigantis.
Gordon Sze	Gordon Sze has nothing to disclose.
Matthew Rosen	Matthew Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for DeepSpin. Matthew Rosen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Chipiron. Matthew Rosen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Synex Medical. Matthew Rosen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Nanalysis. Matthew Rosen has stock in Hyperfine. Matthew Rosen has stock in Q Bio. Matthew Rosen has stock in Vizma Life Sciences. Matthew Rosen has stock in Intact Data Services. The institution of Matthew Rosen has received research support from Imagion. Matthew Rosen has received intellectual property interests from a discovery or technology relating to health care.
W. T. Kimberly, MD, PhD (Massachusetts General Hospital)	Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astrocyte Pharmaceuticals. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acasti Pharma. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hyperfine Inc.. Dr. Kimberly has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurotherapeutics. Dr. Kimberly has stock in Woolsey Pharmaceuticals. Dr. Kimberly has stock in Acasti Pharma. The institution of Dr. Kimberly has received research support from Biogen. The institution of Dr. Kimberly has received research support from NControl Therapeutics. The institution of Dr. Kimberly has received research support from NIH. The institution of Dr. Kimberly has received research support from American Heart Association. The institution of Dr. Kimberly has received research support from Hyperfine, Inc.. Dr. Kimberly has received intellectual property interests from a discovery or technology relating to health care.
Kevin N. Sheth, MD, FAAN (Yale UniversityDivision of Neuro and Critical Care)	Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care.

��ɫ��

��ɫ��